The U.S. Food and Drug Administration has granted Allos Therapeutics, Inc. orphan drug designation for their investigative agent pralatrexate (PDX) in the treatment of diffuse large B-cell and follicular lymphomas.
Pralatrexate inhibits dihydrofolate reductase (DHFR), a folic acid-dependent enzyme involved in the building of nucleic acids and other cellular processes. Pralatrexate is a small-molecular chemotherapy agent that is transported into tumor cells via the reduced folate carrier (RFC-1) and was designed for effective retention once inside tumor cells.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
